Literature DB >> 21820875

Are we addressing the 'right stuff' to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication.

Eva-Marina Beck1, Marialuisa Cavelti, Sara Kvrgic, Birgit Kleim, Roland Vauth.   

Abstract

BACKGROUND: Despite the fact that medication adherence is among the most important health related behaviors in relapse prevention and recovery in schizophrenia, it is often not sufficiently endorsed by patients. Poor insight and negative attitudes towards medication are risk factors for non-adherence. Their relationship and the influence of more general attitudes towards pharmacotherapy besides attitudes towards antipsychotics have not been fully understood. The present study investigated whether these factors independently influence adherence or whether they mediate one another.
METHODS: A cross-sectional sample of 150 outpatients completed the Beliefs about Medication Questionnaire. It assesses patients' beliefs about antipsychotic medication in terms of necessity and concerns and more general beliefs about pharmacotherapy in terms of distrust. Additionally, the patients' global awareness of illness (Scale to assess Unawareness of Mental Disorder), and medication adherence (Brief Adherence Rating Scale, Service Engagement Scale) were assessed.
RESULTS: Using structural equation modeling, the study found evidence for a mediational model. Awareness of illness contributed to medication adherence via patients' perceived necessity of antipsychotics. The model further revealed a direct negative relationship between concerns regarding antipsychotics and adherence and an indirect negative effect of a general distrust regarding pharmacotherapy and adherence via antipsychotic specific attitudes.
CONCLUSION: Interventions to enhance medication adherence may be more effective if they focus on treatment related attitudes rather than on global insight into illness. Clinicians may not only enhance the patients' perceived necessity of antipsychotic treatment but also explore and address concerns and the patients' distrust in pharmacotherapy in a more personalized way.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21820875     DOI: 10.1016/j.schres.2011.07.019

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  28 in total

1.  [Adherence to psychopharmacological treatment: Psychotherapeutic strategies to enhance adherence].

Authors:  R Lencer; D Korn
Journal:  Nervenarzt       Date:  2015-05       Impact factor: 1.214

2.  Using the theory of planned behavior to improve treatment adherence in Mexican Americans with schizophrenia.

Authors:  Alex Kopelowicz; Roberto Zarate; Charles J Wallace; Robert Paul Liberman; Steven R Lopez; Jim Mintz
Journal:  J Consult Clin Psychol       Date:  2015-06-01

Review 3.  The rational patient and beyond: implications for treatment adherence in people with psychiatric disabilities.

Authors:  Patrick W Corrigan; Nicolas Rüsch; Dror Ben-Zeev; Tamara Sher
Journal:  Rehabil Psychol       Date:  2014-01-20

4.  Consumer satisfaction with antipsychotic medication-monitoring appointments: the role of consumer-prescriber communication patterns.

Authors:  Catherine M Reich; Samantha M Hack; Elizabeth A Klingaman; Clayton H Brown; Li Juan Fang; Lisa B Dixon; Danielle R Jahn; Julie A Kreyenbuhl
Journal:  Int J Psychiatry Clin Pract       Date:  2017-09-17       Impact factor: 1.812

5.  Personalizing interventions using real-world interactions: Improving symptoms and social functioning in schizophrenia with tailored metacognitive therapy.

Authors:  Kyle S Minor; Matthew P Marggraf; Beshaun J Davis; Jessica L Mickens; Danielle B Abel; Megan L Robbins; Kelly D Buck; Sarah E Wiehe; Paul H Lysaker
Journal:  J Consult Clin Psychol       Date:  2021-08-19

6.  Families and medication use and adherence among Latinos with schizophrenia.

Authors:  Mercedes Hernandez; Concepción Barrio
Journal:  J Ment Health       Date:  2016-10-01

7.  Beliefs about GI medications and adherence to pharmacotherapy in functional GI disorder outpatients.

Authors:  Benjamin Cassell; C Prakash Gyawali; Vladimir M Kushnir; Britt M Gott; Billy D Nix; Gregory S Sayuk
Journal:  Am J Gastroenterol       Date:  2015-04-28       Impact factor: 10.864

8.  Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention.

Authors:  Richard J Drake; Merete Nordentoft; Gillian Haddock; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Marion Leboyer; Stefan Leucht; Markus Leweke; Phillip McGuire; Andreas Meyer-Lindenberg; Dan Rujescu; Iris E Sommer; René S Kahn; Shon W Lewis
Journal:  Schizophr Bull       Date:  2015-03-05       Impact factor: 9.306

Review 9.  Systematic review reveals heterogeneity in the use of the Scale to Assess Unawareness of Mental Disorder (SUMD).

Authors:  Rémy Dumas; Karine Baumstarck; Pierre Michel; Christophe Lançon; Pascal Auquier; Laurent Boyer
Journal:  Curr Psychiatry Rep       Date:  2013-06       Impact factor: 5.285

10.  Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder.

Authors:  Esteban Medina; Joan Salvà; Rubén Ampudia; Jorge Maurino; Juan Larumbe
Journal:  Patient Prefer Adherence       Date:  2012-08-29       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.